Therapy for acute high-risk pulmonary embolism: Thrombolytic therapy and embolectomy

Current Opinion in Cardiology

Volumn 25, Issue 6, 2010, Pages 560-567

  Meneveau, Nicolas ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

catheter thrombectomy; pulmonary embolism; surgical embolectomy; thrombolysis

Indexed keywords

ALTEPLASE; BRAIN NATRIURETIC PEPTIDE; CONTRAST MEDIUM; DESMOTEPLASE; FATTY ACID BINDING PROTEIN; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; EMBOLECTOMY; HEART MUSCLE INJURY; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMIC MONITORING; HIGH RISK PATIENT; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LOW RISK PATIENT; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MORTALITY; PERCUTANEOUS CATHETER EMBOLECTOMY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; RISK ASSESSMENT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURGICAL TECHNIQUE; SURVIVAL RATE; SYMPTOMATOLOGY;

ACUTE DISEASE; ANTICOAGULANTS; CATHETERIZATION; EMBOLECTOMY; FRANCE; HEPARIN; HUMANS; PROGNOSIS; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 78049263828     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833f02c5     Document Type: Review

References (62)

1. Stein PD, Kayali F, Olson RE. Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol 2004; 93:1197-1199. (Pubitemid 38521063)
2. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240-1245.
3. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389. (Pubitemid 29192409)
4. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30:1165-1171. (Pubitemid 27501430)
5. Kasper W, Konstantinides S, Geibel A, etal. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77:346-349. (Pubitemid 27208175)
6. Laporte S, Mismetti P, Decousus H, et al. Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad Trombo Embolica venosa (RIETE) Registry. Circulation 2008; 117:1711-1716. (Pubitemid 351482603)
7. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29:2276-2315.
8. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006; 113:577-582. (Pubitemid 43754359)
9. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108:978-981.
10. Lankeit M, Konstantinides S. Thrombolysis for pulmonary embolism: past, present and future. Thromb Haemost 2010; 103:877-883.
11. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20:520-526.
12. The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973; 47(2 Suppl):II1-II108.
13. Konstantinides S, Tiede N, Geibel A, et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998; 82:966-970. (Pubitemid 28480783)
14. Goldhaber SZ. Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy. J Thromb Haemost 2009; 7 (Suppl 1):322-327.
15. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-511.
16. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203:465-470. (Pubitemid 8358211)
17. Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80:184-188. (Pubitemid 27329218)
18. Meneveau N, Seronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129:1043-1050.
19. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: A meta-analysis of the randomized controlled trials. Circulation 2004; 110:744-749. (Pubitemid 39056276)
20. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptoki-nase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2:227-229.
21. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S-545S. (Pubitemid 351892971)
22. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143-1150.
23. Binder L, Pieske B, Olschewski M, et al. N-Terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112:1573-1579. (Pubitemid 41324518)
24. Giannitsis E, Katus HA. Risk stratification in pulmonary embolism based on biomarkers and echocardiography. Circulation 2005; 112:1520-1521. (Pubitemid 41324509)
25. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545-2547. (Pubitemid 36628932)
26. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: A systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178:425-430.
27. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92:987-993. (Pubitemid 43974074)
28. Lankeit M, Konstantinides S. Tenecteplase can be given to patients with intermediate-risk pulmonary embolism-But should it? Thromb Res 2009. [Epub ahead of print]
29. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004; 97:187-198.
30. Kaczynska A, Pelsers MM, Bochowicz A, et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta 2006; 371:117-123. (Pubitemid 44162903)
31. Puls M, Dellas C, Lankeit M, et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28:224-229. (Pubitemid 46269875)
32. Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177:1018-1025 (Pubitemid 351717597)
33. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. JAMA 1974; 229:1606-1613.
34. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 2:293-298.
35. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasmino-gen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20:24-30.
36. Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111:1241-1245.
37. Konstantinides S, Marder VJ. Thrombolysis in venous thromboembolism. In: Colman RW, Marder VJ, Clowes AW, et al., editors. Hemostasis and Thrombosis. 5th ed. Lippincott Williams and Wilkins; 2006. pp. 1317-1329.
38. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98:1473-1479.
39. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: A European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. JAm Coll Cardiol 1992; 19:239-245.
40. Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106:712-717.
41. Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77:353-360. (Pubitemid 18060044)
42. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of non-invasive management. Ann Intern Med 1994; 121:313-317.
43. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359:2804-2813. (Pubitemid 351744706)
44. Hamel E, Pacouret G, Vincentelli D, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001; 120:120-125. (Pubitemid 32744867)
45. Meyer G, Gisselbrecht M, Diehl JL, et al. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105:472-477. (Pubitemid 29013331)
46. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998; 31:1057-1063. (Pubitemid 28212506)
47. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart hae-modynamics and pulmonary vascular obstruction. Eur Heart J 1997; 18: 1141-1148. (Pubitemid 27271887)
48. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest 1994; 106:718-724. (Pubitemid 24278871)
49. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999; 138:39-44. (Pubitemid 29331118)
50. Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125:e82-e86.
51. Tebbe U, Bramlage P, Graf A, etal. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009; 101:557-562.
52. Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. JThorac Cardiovasc Surg 2005; 129:1018-1023. (Pubitemid 40631421)
53. Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolect-omy: A contemporary approach. Circulation 2002; 105:1416-1419. (Pubitemid 34263270)
54. Skaf E, Beemath A, Siddiqui T, et al. Catheter-tip embolectomy in the management of acute massive pulmonary embolism. Am J Cardiol 2007; 99:415-420. (Pubitemid 46149564)
55. Kucher N. Catheter embolectomy for acute pulmonary embolism. Chest 2007; 132:657-663. (Pubitemid 47282401)
56. Margheri M, Vittori G, Vecchio S, et al. Early and long-term clinical results of Angio Jet rheolytic thrombectomy in patients with acute pulmonary embolism. Am J Cardiol 2008; 101:252-258.
57. Greenfield LJ, Proctor MC, Williams DM, Wakefield TW. Long-term experience with transvenous catheter pulmonary embolectomy. J Vasc Surg 1993; 18:450-457; discussion 457-458.
58. Muller-Hulsbeck S, Brossmann J,Jahnke T, et al. Mechanicalthrombectomy of major and massive pulmonary embolism with use of the Amplatz thrombect-omy device. Invest Radiol 2001; 36:317-322. (Pubitemid 32553415)
59. Fava M, Loyola S, Huete I. Massive pulmonary embolism: treatment with the hydrolyser thrombectomy catheter. J Vasc Interv Radiol 2000; 11:1159-1164.
60. Koning R, Cribier A, Gerber L, et al. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. Circulation 1997; 96:2498-2500. (Pubitemid 27451335)
61. Sharafuddin MJ, Hicks ME. Current status of percutaneous mechanical thrombectomy. Part I. General principles. J Vasc Interv Radiol 1997; 8: 911-921.
62. Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112:e28-e32.